Shopping Cart
Remove All
Your shopping cart is currently empty
Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $38 | In Stock | In Stock | |
| 10 mg | $61 | In Stock | In Stock | |
| 25 mg | $121 | In Stock | In Stock | |
| 50 mg | $188 | In Stock | In Stock | |
| 100 mg | $312 | In Stock | In Stock | |
| 200 mg | $538 | Backorder | Backorder | |
| 1 mL x 10 mM (in DMSO) | $42 | In Stock | In Stock |
| Description | Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease. |
| Targets&IC50 | AhR:13 nM(EC50) |
| In vitro | Tapinarof activates the AhR pathway through direct binding, inducing dose-dependent nuclear translocation of AhR in immortalized keratinocytes (HaCaT). |
| In vivo | Tapinarof mediates its anti-inflammatory effects via the AhR pathway in IMQ-treated mice. In mice expressing AhR on a C57Bl/6 background, both Tapinarof and 6-formylindolo(3,2-b)carbazole (FICZ) significantly lower clinical inflammation scores. Conversely, AhR knockout (KO) mice exhibit no such anti-inflammatory response to Tapinarof. FICZ serves as a benchmark in these experiments, demonstrating comparable reduction in inflammation in wild-type mice, but ineffective in AhR KO mice. |
| Synonyms | WBI 1001, GSK2894512, Benvitimod |
| Molecular Weight | 254.32 |
| Formula | C17H18O2 |
| Cas No. | 79338-84-4 |
| Smiles | CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O |
| Relative Density. | 1.158 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (216.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.86 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.